Clinical Trial Update: The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating 177Lu-DOTA-rosopatamab plus standard of care versus standard of care alone in metastatic prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 177Lu-DOTA-rosopatamab

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd | Conditions: Metastatic Prostate Cancer | Phase 3 | Status: TERMINATED